Apply for funding to develop a broad utility, deep genotyping and phenotyping platform capable of generating insights into patient response, adverse effects, and resistance to immunotherapy, and exemplar project(s) to demonstrate utility.
The platform will be led by a multi-organisational and multidisciplinary consortium, including at least one industry partner.
A total of £9 million (80% Full Economic cost (FEC) including relevant indexing) over four years is available with £4 million in FY 2024/25.
You must be a researcher employed at a research organisation eligible to apply for Medical Research Council (MRC) funding.
Opportunity status: Open
Funders: Medical Research Council (MRC)
Co-funders: Office of Life Sciences
Funding type: Grant
Total fund: £9,000,000
Maximum award: £9,000,000
Publication date: 9 January 2024
Opening date: 25 January 2024 9:00am UK time
Closing date: 9 May 2024 4:00pm UK time
